HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.

Abstract
Prostate cancer (PCa) is now the most prevalent cancer in men in the U.S.A. and Europe. At present the major treatment options include surgical or medical castration. These strategies depend on the abolition of the production of testosterone by the testes. However, as these procedures do not affect adrenal androgen production, they are frequently combined with androgen receptor antagonist to block their action. Inhibition of the key enzyme which catalyzes the biosynthesis of androgens from pregnane precursors, 17alpha-hydroxylase/17,20-lyase (hereafter referred to as CYP17 ) could prevent androgen biosynthesis from both sources. Thus total blockade of androgen production by CYP17 inhibitors may provide effective treatment of prostate cancer patients. Indeed, this strategy is now an area of intense interest within research institutions and the pharmaceutical industry. This review highlights development in the design and evaluation of both steroidal and non-steroidal CYP17 inhibitors since 1965. Major emphasis is given to the potent CYP17 inhibitors and those which may show clinical promise. The review could function as a comprehensive working reference of research accomplishment in the field and what problems remain to be tackled in the future.
AuthorsV C Njar, A M Brodie
JournalCurrent pharmaceutical design (Curr Pharm Des) Vol. 5 Issue 3 Pg. 163-80 (Mar 1999) ISSN: 1381-6128 [Print] United Arab Emirates
PMID10066888 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Affinity Labels
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Oxidoreductases
  • Steroid 17-alpha-Hydroxylase
  • Cholestenone 5 alpha-Reductase
Topics
  • Affinity Labels (therapeutic use)
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Cholestenone 5 alpha-Reductase
  • Enzyme Inhibitors (therapeutic use)
  • Humans
  • Male
  • Oxidoreductases (antagonists & inhibitors)
  • Prostatic Neoplasms (drug therapy, enzymology)
  • Steroid 17-alpha-Hydroxylase (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: